<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-49289" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Instantaneous Wave-Free Ratio</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Soos</surname>
            <given-names>Michael P.</given-names>
          </name>
          <aff>McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gonzalez-Morales</surname>
            <given-names>Daniel</given-names>
          </name>
          <aff>McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McComb</surname>
            <given-names>David</given-names>
          </name>
          <aff>Michigan State University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Michael Soos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Gonzalez-Morales declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David McComb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>4</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-49289.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Coronary artery disease is the leading cause of death in men and women in the United States. The instantaneous wave-free ratio (iFR) can be used to determine whether or not coronary lesions that are visualized angiographically should undergo percutaneous intervention. This activity describes the instantaneous wave-free ratio and its use in the cardiac catheterization lab to determine the hemodynamic significance of coronary lesions and highlights the role of the interprofessional team in caring for percutaneous coronary intervention candidates.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the technical aspects of the instantaneous wave-free ratio (iFR).</p></list-item><list-item><p>Determine how the instantaneous wave-free ratio is used in the management of coronary artery disease.</p></list-item><list-item><p>Identify instantaneous wave-free ratio values at which coronary lesions are determined to be hemodynamically unstable and therefore should undergo percutaneous intervention.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration amongst the interprofessional team to ensure the appropriate selection of candidates for percutaneous intervention.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=49289&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=49289">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-49289.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Coronary artery disease (CAD) is a common pathologic process affecting more than 15 million Americans every year.<xref ref-type="bibr" rid="article-49289.r1">[1]</xref>&#x000a0;Currently, it is listed as the most common cause of death in both men and women, accounting for 24.2% and 22.0% of all deaths, respectively, in 2016. CAD is characterized by a narrowing or blockage within the coronary arteries, often related to atherosclerosis. CAD, when significant, often results in reduced and inadequate blood flow to the myocardium leading to myocardial injury related to diminished oxygen and nutrient supply. Myocardial injury related to CAD often presents clinically as an acute coronary syndrome (ACS), including unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI). ACS is a group of conditions characterized by angina or anginal equivalents that require emergency medical evaluation and treatment.</p>
        <p>Cardiac catheterization with angiography is a minimally invasive diagnostic procedure and imaging modality that has become a mainstay in evaluating CAD.<xref ref-type="bibr" rid="article-49289.r2">[2]</xref> During catheterization, a sheath gets introduced to the arterial system via either the femoral or, increasingly more commonly, the radial artery. A catheter is then advanced through the arterial system under fluoroscopy to the aortic root. Iodinated contrast is then utilized to visualize the aortic valve cusps and gain access to the right and left coronary arteries. After gaining access to individual coronary arteries utilizing a variety of guidewires, angiography is performed utilizing contrast to identify significant stenosis, atherosclerotic lesions, or blockages within individual arteries. Historically, the significance of these lesions has been determined by visual approximation and estimation performed by a cardiologist trained in either diagnostic or interventional cardiac catheterization. A study published in February 2018 evaluated coronary artery lesions treated with percutaneous coronary intervention (PCI) in China confirmed that physician visual assessment (PVA) of stenosis resulted in higher readings of stenosis severity when compared with quantitative coronary angiography (QCA). Additionally, the study revealed significant variations across hospitals and physicians, confirming the utility of additional diagnostic studies.<xref ref-type="bibr" rid="article-49289.r3">[3]</xref></p>
        <p>Significant lesions, those with greater than 70% luminal narrowing, via visual estimation qualify for intervention utilizing techniques such as balloon angioplasty or percutaneous intervention with coronary artery stent placement. Lesions displaying less than 40% stenosis are determined non-significant, and the recommendation in these cases is to optimize medical therapy for treating CAD. Interventions in patients with indeterminate lesions, between 40% and 70% stenosis, previously were subject to debate. In the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE, 2007), revascularization with PCI in stable CAD with high-grade stenosis failed to display benefit over optimal medical therapy.<xref ref-type="bibr" rid="article-49289.r4">[4]</xref></p>
        <p>Additional diagnostic modalities have been developed to characterize these lesions better and identify those that would benefit from intervention, including fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR). FFR is described in depth within its review article; however, FFR is a guidewire-based technique that measures blood pressure and flows through a specific lesion. The DEFER trial (2007) determined that the 5-year, event-free survival was not significantly different between patients who performed and deferred PCI on intermediate coronary stenosis with an FFR greater than 0.75.<xref ref-type="bibr" rid="article-49289.r5">[5]</xref> In the study, fractional flow reserve versus angiography for guiding percutaneous coronary intervention (FAME), FFR-guided PCI reduced composites of death, nonfatal myocardial infarction (MI), and repeat revascularization at&#x000a0;1 year compared with standard PCI alone.<xref ref-type="bibr" rid="article-49289.r6">[6]</xref> In FFR, the interventionist utilizes a specialized guidewire to measure flow velocities and pressure across a target lesion. Following administering a hyperemic agent, typically adenosine, the FFR value is calculated. Studies have suggested that lesions with an FFR value of less than 0.75 are suspicious for inducible ischemia and would benefit from PCI. In contrast, those with values greater than 0.75 are candidates for treatment with optimum medical therapy.&#x000a0;</p>
        <p>iFR is a newer physiologic measurement that utilizes principles similar to FFR but does not require a hyperemic agent. In a 2017 JACC study, iFR and FFR demonstrated no significant differences in the prediction of myocardial ischemia.<xref ref-type="bibr" rid="article-49289.r7">[7]</xref> The MACE trial further justified using iFR, revealing that IiR-guided revascularization was non-inferior to FFR-guided revascularization for major adverse cardiac events at 1-year follow-up.<xref ref-type="bibr" rid="article-49289.r8">[8]</xref> In iFR, the same pressure wires utilized in FFR get passed to a point distal to a stenotic lesion. During a period of diastole known as the &#x0201c;wave-free period,&#x0201d; iFR then calculates the ratio of the distal coronary artery pressure (Pd) to the pressure within the aortic outflow tract (Pa). During this timeframe completing blood flow complicating these measurements is negligible. Lesions found to have a Pd/Pa ratio less than 0.89 are determined to be significant and are non-inferior to the FFR cutoff of 0.8.<xref ref-type="bibr" rid="article-49289.r9">[9]</xref><xref ref-type="bibr" rid="article-49289.r10">[10]</xref> Coronary artery lesions with iFR ratios less than 0.89 and FFR ratios less than 0.8 are recommended for further treatment with PCI. As it is still a newer technology, some providers consider an iFR ratio of 0.86 to 0.93 an area of uncertainty and recommend a hybrid approach utilizing evaluation with FFR.</p>
      </sec>
      <sec id="article-49289.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Relevant anatomy utilized during iFR is relatively limited, but detailed knowledge of the coronary vasculature is recommended and is reviewed elsewhere.</p>
      </sec>
      <sec id="article-49289.s4" sec-type="Indications">
        <title>Indications</title>
        <p>Indications for iFR are in patients with stable CAD and indeterminate lesions, between 40% and 70% stenosis.</p>
      </sec>
      <sec id="article-49289.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are no contraindications at this time for iFR. However, current recommendations for iFR do not include patients with ACS.&#x000a0;</p>
      </sec>
      <sec id="article-49289.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>iFR requires a specialized guidewire with pressure and flow velocity sensing capabilities and computer software that accurately calculates iFR values. Additional equipment, including the vascular sheath, cardiac catheters, and imaging modalities, are unchanged from traditional cardiac catheterization.</p>
      </sec>
      <sec id="article-49289.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>iFR should be performed only by board-certified cardiologists with formal training in interventional cardiac catheterization.</p>
      </sec>
      <sec id="article-49289.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>Once the computer software for calculating iFR is installed and specialized catheters are available, minimal additional setup is required compared to standard cardiac catheterization.</p>
      </sec>
      <sec id="article-49289.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>In iFR, the same pressure wires utilized in FFR are passed to a point distal to a stenotic lesion. During a period of diastole known as the &#x0201c;wave-free period,&#x0201d; IiR then calculates the ratio of the distal coronary artery pressure (Pd) to the pressure within the aortic outflow tract (Pa). During this timeframe, completing blood flow complicating these measurements is negligible.</p>
      </sec>
      <sec id="article-49289.s10" sec-type="Complications">
        <title>Complications</title>
        <p>There are minimal complications associated directly with iFR; however, they are the same as those of a standard cardiac catheterization with angiography and PCI and include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleeding</p>
          </list-item>
          <list-item>
            <p>Access site hematoma and pseudoaneurysm</p>
          </list-item>
          <list-item>
            <p>Acute kidney injury caused by the contrast agent</p>
          </list-item>
          <list-item>
            <p>Anaphylaxis caused by the contrast agent</p>
          </list-item>
          <list-item>
            <p>Coronary artery dissection</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-49289.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Clinically, iFR may be utilized to assess indeterminate coronary artery stenosis further for lesions anywhere from 40% to 90%, but recommendations do not include patients with ACS. Patients with clinical symptoms or non-invasive testing consistent with ischemia and an iFR of 0.89 or less are candidates for PCI. While a patient with an iFR greater than 0.93 typically qualifies for optimization of medical therapy (OMT), those with a ratio of 0.90 to 0.93 should have a follow-up with FFR. In a patient with clinical symptoms not consistent with ischemia, PCI is recommended for iFR under 0.86. In those with an iFR ratio over 0.89, OMT is recommended. Patients with iFR ratios between 0.86 and 0.89 are recommended for FFR confirmation (see<bold>&#x000a0;Image.</bold> iFR Flow Chart).<xref ref-type="bibr" rid="article-49289.r11">[11]</xref></p>
      </sec>
      <sec id="article-49289.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In late 2018, the European Society of Cardiology (ESC) announced that it had incorporated iFR into its updated revascularization guidelines. The recommendations noted that iFR should be performed alongside FFR to objectively assess coronary lesions' hemodynamic relevance. The current AHA/ACC guidelines do not formally address using iFR during coronary revascularization. While an invasive cardiologist performs the procedure, the rest of the healthcare team should inform the patient about the importance of lifestyle changes in lowering the risk of coronary artery disease.</p>
      </sec>
      <sec id="article-49289.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=49289&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=49289">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/49289/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=49289">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-49289.s14">
        <fig id="article-49289.image.f1" position="float" orientation="portrait">
          <caption>
            <p>iFR Flow Chart. Determines the significance of indeterminate coronary artery lesions. Shlofmitz E, Jeremias A. FFR in 2017: Current Status in PCI Management. American College of Cardiology.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="2017May25_Shlofmitz_Jeremias_Fig2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-49289.s15">
        <title>References</title>
        <ref id="article-49289.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanchis-Gomar</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Perez-Quilis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leischik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lucia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of coronary heart disease and acute coronary syndrome.</article-title>
            <source>Ann Transl Med</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>4</volume>
            <issue>13</issue>
            <fpage>256</fpage>
            <pub-id pub-id-type="pmid">27500157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Libby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Theroux</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology of coronary artery disease.</article-title>
            <source>Circulation</source>
            <year>2005</year>
            <month>Jun</month>
            <day>28</day>
            <volume>111</volume>
            <issue>25</issue>
            <fpage>3481</fpage>
            <page-range>3481-8</page-range>
            <pub-id pub-id-type="pmid">15983262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nallamothu</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Lansky</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bouras</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ge</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>L</given-names>
              </name>
              <collab>China PEACE Collaborative Group</collab>
            </person-group>
            <article-title>Comparison of Physician Visual Assessment With Quantitative Coronary Angiography in Assessment of Stenosis Severity in China.</article-title>
            <source>JAMA Intern Med</source>
            <year>2018</year>
            <month>Feb</month>
            <day>01</day>
            <volume>178</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-247</page-range>
            <pub-id pub-id-type="pmid">29340571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boden</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>O'Rourke</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Teo</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Hartigan</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Maron</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Kostuk</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Knudtson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Casperson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chaitman</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nawaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Title</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Gau</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Blaustein</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Bates</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Spertus</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Berman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Mancini</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Weintraub</surname>
                <given-names>WS</given-names>
              </name>
              <collab>COURAGE Trial Research Group</collab>
            </person-group>
            <article-title>Optimal medical therapy with or without PCI for stable coronary disease.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Apr</month>
            <day>12</day>
            <volume>356</volume>
            <issue>15</issue>
            <fpage>1503</fpage>
            <page-range>1503-16</page-range>
            <pub-id pub-id-type="pmid">17387127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zimmermann</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>van Nunen</surname>
                <given-names>LX</given-names>
              </name>
              <name>
                <surname>Escaned</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Albertsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Erbel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Legrand</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gwon</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Remkes</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Stella</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>van Schaardenburgh</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bech</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial.</article-title>
            <source>Eur Heart J</source>
            <year>2015</year>
            <month>Dec</month>
            <day>01</day>
            <volume>36</volume>
            <issue>45</issue>
            <fpage>3182</fpage>
            <page-range>3182-8</page-range>
            <pub-id pub-id-type="pmid">26400825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tonino</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Siebert</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ikeno</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van' t Veer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klauss</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Manoharan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Engstr&#x000f8;m</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Ver Lee</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>MacCarthy</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <collab>FAME Study Investigators</collab>
            </person-group>
            <article-title>Fractional flow reserve versus angiography for guiding percutaneous coronary intervention.</article-title>
            <source>N Engl J Med</source>
            <year>2009</year>
            <month>Jan</month>
            <day>15</day>
            <volume>360</volume>
            <issue>3</issue>
            <fpage>213</fpage>
            <page-range>213-24</page-range>
            <pub-id pub-id-type="pmid">19144937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Suh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Paeng</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Na</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Cheon</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Cook</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic Performance of Resting and Hyperemic Invasive Physiological Indices to Define Myocardial Ischemia: Validation With <sup>13</sup>N-Ammonia Positron Emission Tomography.</article-title>
            <source>JACC Cardiovasc Interv</source>
            <year>2017</year>
            <month>Apr</month>
            <day>24</day>
            <volume>10</volume>
            <issue>8</issue>
            <fpage>751</fpage>
            <page-range>751-760</page-range>
            <pub-id pub-id-type="pmid">28365268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f6;tberg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Christiansen</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Gudmundsdottir</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Sandhall</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Danielewicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jakobsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>&#x000d6;hagen</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Olsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Omerovic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Calais</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lindroos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maeng</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>T&#x000f6;dt</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Venetsanos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>K&#x000e5;regren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hauer</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Panayi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Erlinge</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fr&#x000f6;bert</surname>
                <given-names>O</given-names>
              </name>
              <collab>iFR-SWEDEHEART Investigators</collab>
            </person-group>
            <article-title>Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>11</day>
            <volume>376</volume>
            <issue>19</issue>
            <fpage>1813</fpage>
            <page-range>1813-1823</page-range>
            <pub-id pub-id-type="pmid">28317438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van 't Veer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kala</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bocek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pyxaras</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>McClure</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Barbato</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tonino</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>KG</given-names>
              </name>
            </person-group>
            <article-title>VERIFY (VERification of Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Coronary Artery Stenosis Severity in EverydaY Practice): a multicenter study in consecutive patients.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Apr</month>
            <day>02</day>
            <volume>61</volume>
            <issue>13</issue>
            <fpage>1421</fpage>
            <page-range>1421-7</page-range>
            <pub-id pub-id-type="pmid">23395076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeremias</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maehara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>G&#x000e9;n&#x000e9;reux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Asrress</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>De Bruyne</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Escaned</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fearon</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Kirtane</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Koo</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Nijjer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oldroyd</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Petraco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Piek</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pijls</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Redwood</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siebes</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Spaan</surname>
                <given-names>JAE</given-names>
              </name>
              <name>
                <surname>van 't Veer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mintz</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>Multicenter core laboratory comparison of the instantaneous wave-free ratio and resting Pd/Pa with fractional flow reserve: the RESOLVE study.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Apr</month>
            <day>08</day>
            <volume>63</volume>
            <issue>13</issue>
            <fpage>1253</fpage>
            <page-range>1253-1261</page-range>
            <pub-id pub-id-type="pmid">24211503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-49289.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coughlan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>MacDonnell</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arnous</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kiernan</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Fractional flow reserve in 2017: current data and everyday practice.</article-title>
            <source>Expert Rev Cardiovasc Ther</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>457</fpage>
            <page-range>457-472</page-range>
            <pub-id pub-id-type="pmid">28475383</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
